球菌类毒素联合内分泌药物治疗晚期复发性乳腺癌临床研究

金宗浩, 党云文

金宗浩, 党云文. 球菌类毒素联合内分泌药物治疗晚期复发性乳腺癌临床研究[J]. 中国肿瘤临床, 2005, 32(1): 34-36.
引用本文: 金宗浩, 党云文. 球菌类毒素联合内分泌药物治疗晚期复发性乳腺癌临床研究[J]. 中国肿瘤临床, 2005, 32(1): 34-36.
shu
Jin Zonghao, Dang Yunwen. Clinical Study on Recurrence of Advanced Breast Cancer Treated by LIFEIN in Combination with Incretion Drug[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 32(1): 34-36.
Citation: Jin Zonghao, Dang Yunwen. Clinical Study on Recurrence of Advanced Breast Cancer Treated by LIFEIN in Combination with Incretion Drug[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 32(1): 34-36.
shu

球菌类毒素联合内分泌药物治疗晚期复发性乳腺癌临床研究

  • 同济大学附属同济医院乳腺外科, 上海市 200065

详细信息

  • 中图分类号: R737.9

Clinical Study on Recurrence of Advanced Breast Cancer Treated by LIFEIN in Combination with Incretion Drug

  • Department of Breast Surgery, Tongji Hospital of Tongji University, Shanghai

摘要

    摘要
  • 摘要: 目的:研究球菌类毒素制剂在提高晚期复发性乳腺癌治疗效果方面的作用。方法:78例有局部复发或远处转移的晚期乳腺癌患者,随机分为治疗组(35例)和对照组(43例)。治疗组应用球菌类毒素甘露聚糖肽(制剂名“力尔凡”由长春力尔凡药业有限公司提供),联合法乐通治疗;对照组单用法乐通治疗。力尔凡应用方法:第1～7d皮下注射力尔凡10mg/d,第8～14d静脉滴注20mg/d,15～21d静脉滴注30mg/d,22～28d静脉滴注30mg/d,29～64d静脉滴注40mg/d。法乐通60mg/d,口服共64d。全部病例的疗效用显效(CR)、有效(PR)、无效(NC)、进展(PD)、有效率(CR+PR)等进行临床评估,用癌胚抗原(Carcino-embryonicantigen,CEA)、糖类抗原CA-153检测进行实验室评估。结果:全部病例均按要求完成治疗。治疗组总缓解率为94.29%,对照组为76.74%(P<0.01)。结论:力尔凡与内分泌治疗药物联合应用,能提高晚期复发性乳腺癌患者的生存质量和生存率。
    Abstract: Objective:To study the improved therapeutic effect of LIFEIN for the patients with recurrence of advanced breast cancer. Methods: Seventy-eight cases of advanced breast cancers with local recurrent metastases were divided into two groups: the treatment group (35 cases) and the controls(43 cases). The treatment group was treated by LIFEIN combining with Fareston incretion medical, and the control group treated with Fareston alone. The treatment method of LIFEIN: 10mg/d x7 subcuta-neously; then 20mg/dx7, 30mg/dx7 and 40m/dx36, intravenously and successively. Endocrine therapy with Fareston: 60mg/d orally for 64 days. All the cases were evaluated with CR,PR,NC,PD and effective rate. With Carcin(卜embryonic antigen (CEA) and CA一153. Results: The treatemnts were completed in all the patients. The efficacy was 85.71% in the treatment group and 76.74% in the controls (P>0.01). Conclusion: LIFEIN can improve the survival rate and life quality of the patients with metastries of breast cancer.
    • HTML全文
    • 参考文献(14)
  • [1] Golleoni M, Neill AO, Goldhirsch A, et al. Identify breast cancer patients at high risk for bone metastases[J]·Glin Onool, 2000, 18(8):3925~3930.
    [2] Rouzier R, Extra JM, Garton M, et al. Primary chemotherapy for operable breast cancer: incidence and pro}ostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery[J]. J Glin Oncol, 2001, 19(12): 3798~3800.
    [3] Park GG, Mitsumori M, Nixon A, et al. Outcome at 8 years after breast -conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence[J]. J Glin Oncol, 2000, 18(8): 1668~1675.
    [4] 刘振华, 主编.肿瘤预后学M.北京:科学技术文献出版社, 1995.198 [J] 201.
    [5] 金宗浩, 主编.乳腺增生与乳腺癌M.上海:上海科学技术文献出版辛1,2002.190~223.
    [6] Veronesi U, Gascinell N, Mariani LI went)一)ear follow-up of a randomized study comparing breast -conserving surgery with radical mastectomy for early breast cancer [J]. N Engl J Med,2002, 347(16): 1227~1232.
    [7] Bermudes D, Zheng LM, King LG. Live bacteria as anticancer a gents and tumor-selective protein delivery vectors[J].Gurr Opin Drug Discover Devel, 2002, 5(2): 194~199.
    [8] 张弘纲, 孙燕.力尔凡合并化疗、放疗治疗恶性肿瘤的多中心临床研究[J].中国肿瘤临床, 2001,28(4) :282~287.
    [9] 张天泽, 徐光炜, 主编.肿瘤学阿[M].天津:天津科学技术出版社, 1998.771.
    [10] Gostantion[J], Wickerbam DL, Osin P, et al. Tamoxifen for pre vention of breast cancer report of the National Surgical Adjuvant breast and Bowel Project P-1 Study [J].Natl Gancer Inst, 1998,90 (18) : 1371~1388.
    [11] AlbertAJ, Lam AP, Helzlsouer匆.Epidemiology prevention and early detection of breast cancer [J]. Gurr Oncol, 1999, 11 (9):935~941.
    [12] Komi J, Zhang TB, Kononen J, et al. Antiestrogens enbance to mour necrosis factor receptor 2 expressions and TNF-R2-mediated proliferation in activated T cells[J]. Scand J Immunol, 1998.48(3): 254~260.
    [13] SimpsonRJ, Dorow DS. Gancer proteomics: from signaling net works to markers[J]. Trends Biotechnol, 2001, 19(10 Supply: s40~s48.
    [14] 金宗浩, 主编.当代乳腺癌的诊断和治疗[M].上海:上海科学技术文献出版.2000.251~260.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  2
  • HTML全文浏览量:  0
  • PDF下载量:  1
  • 被引次数: 0
出版历程
  • 收稿日期:  2004-02-29
  • 发布日期:  2005-01-14

目录

摘要
HTML全文
    参考文献(14)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    版权所有 © 2013《中国肿瘤临床》编辑部津ICP备09011441号-3

    地址：天津市河西区体院北环湖西路肿瘤医院内 300060电话/传真：(022)23527053Email：cjco@cjco.cn

    本系统由北京仁和汇智信息技术有限公司开发  百度统计